Cell Bio Human Tech셀바이오휴먼텍

Cell Bio Human Tech shows strong trailing profits and revenue growth in 2025, but its share price has fallen sharply over the past year.

Cell Bio Human Tech makes sheet mask materials, hydrocolloid patches and, since 2025, cosmetic OEM products. Trailing twelve-month revenue to H1 2026 was about ₩60.9B with an operating margin of 16.1%, and the shares closed at ₩6,580, down 32.9% over one year. The data does not include any analyst ratings or news coverage, so the picture rests on filings and the numbers alone.

What stands out

• Revenue rose from ₩28.4B in 2024 to ₩51.1B in 2025, growth of 79.7%, and operating income reached ₩9.3B.
• Trailing free cash flow was negative at about -₩6.4B, even though net income was ₩10.6B, which points to heavy cash use in the period.
• Borrowings of ₩11.8B exceed cash of ₩11.0B, and liabilities are 44.7% of equity.
• Valuation metrics are low: P/E of 5.8, P/B of 1.0, and a DCF base value of ₩23,154 against the ₩6,580 close, with the bear and bull cases at ₩15,031 and ₩36,346. The model is a formula output, not a forecast.
• Filings include a share buyback trust contract signed in June 2026 and its termination, with status reports continuing into September, plus a 5%+ holding report and an IR event in August.

What to watch

• Next quarterly results and whether free cash flow turns positive, since the data shows a negative trailing figure.
• Status reports on the share acquisition trust, which will show how the buyback is progressing.
• The stock fell 11.1% over one month and 32.9% over one year, and foreign ownership rose slightly to 4.3%; the data does not explain these moves.